Acumen exercises option for JCR technology
Acumen Pharmaceuticals (NASDAQ:ABOS) executed its exclusive option to develop and manufacture two Alzheimer's disease treatment candidates using the proprietary blood-brain barrier (BBB)-penetrating platform from JCR Pharmaceuticals (TSE:4552).







-640x360.webp&w=3840&q=75)















